Scancell Holdings plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCLP.L research report →
Companywww.scancell.co.uk
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens.
- CEO
- Phillip John L'Huillier
- IPO
- 2010
- Employees
- 61
- HQ
- Oxford, GB
Price Chart
Valuation
- Market Cap
- $223.12M
- P/E
- -40.47
- P/S
- 47.36
- P/B
- -26.64
- EV/EBITDA
- -41.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.45%
- Op Margin
- -283.34%
- Net Margin
- -116.98%
- ROE
- 90.29%
- ROIC
- -113.84%
Growth & Income
- Revenue
- $4.71M · 0.00%
- Net Income
- $-12,272,000 · -109.46%
- EPS
- $-0.01 · -85.29%
- Op Income
- $-15,001,000
- FCF YoY
- 61.36%
Performance & Tape
- 52W High
- $29.50
- 52W Low
- $7.86
- 50D MA
- $14.31
- 200D MA
- $11.61
- Beta
- 0.57
- Avg Volume
- 1.94M
Get TickerSpark's AI analysis on SCLP.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SCLP.L Coverage
We haven't published any research on SCLP.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SCLP.L Report →